Bulk Drugs: Clinical Trials

29 trials of Bulk Drugs, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 3 unknown, 2 not yet recruiting, 2 recruiting. 15 Phase 2, 8 Phase 1, 6 Phase 3, 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 215Completed 9, Unknown 3, Recruiting 2, Suspended 1
Phase 18Completed 6, Active not recruiting 1, Not yet recruiting 1
Phase 36Completed 1, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 43Completed 2, Terminated 1

Follow Bulk Drugs: new trials by email Literature Review of Bulk Drugs trials Research Report on Bulk Drugs

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open-label, Single-arm Trial of Ganaxolone in CDD Patients 6 Months to Less Than 2 Years Old
Ganaxolone - CDKL5 Deficiency Disorder
Phase 3Not yet recruitingImmedica Pharma AB122027-03-012026-11-04
Study of AB-110 in Healthy and Hypertensive Participants
Active drug, AB-110 Matching Placebo - Hypertension (HTN), Healthy Adult Participants
Phase 1Not yet recruitingAntlia Bioscience, Inc1042026-11-012026-11-04
Predicting Response to Naltrexone With Eye Tracking in Gaming Disorder
Naltrexone group A, Naltrexone, Psychoeducational - Gaming Disorder
Phase 2RecruitingUniversity of Sao Paulo402026-07-012026-07-27
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
SC1011, Placebo comparator - Idiopathic Pulmonary Fibrosis
Phase 2 / Phase 3RecruitingGuangzhou JOYO Pharma Co., Ltd2102023-06-062024-11-19
Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease
Dapagliflozin 10mg Tab, Placebo - Myocardial Ischemia
Phase 1CompletedUniversity of Virginia352023-06-062026-11-06
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
RGT-419B - Breast Cancer, Advanced Solid Tumor
Phase 1Active not recruitingRegor Pharmaceuticals Inc.402023-04-172026-08-27
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
Letermovir - Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients
Phase 4CompletedTufts Medical Center212023-02-022026-10-26
Safety and Efficacy of HB-1 for Panic Disorder
HB-01, Placebo - Panic Disorder
Phase 2CompletedHB BioTech, LLC862022-02-032025-03-18
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
Sham Injector, FAI Insert - Uveitis, Uveitis, Posterior
Phase 3TerminatedEyePoint Pharmaceuticals, Inc.122021-10-132024-12-19
Optimal Peripheral Nerve Block After Minimally Invasive Colon Surgery
Active drug, Placebo, Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block - Pain, Postoperative, Pain, Abdominal
Phase 4CompletedClaus Anders Bertelsen, PhD, MD3602021-01-142025-08-07
Pharmacokinetics of PN-235 in Healthy Volunteers
PN-235, Placebo - Healthy Volunteers
Phase 1CompletedProtagonist Therapeutics, Inc.1072020-11-122022-02-18
Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
Patiromer Powder for Oral Suspension [Veltassa], Placebo - Hyperkalemia
Phase 4TerminatedComprehensive Research Associates1152020-10-082023-08-31
Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
LB-102 - Schizophrenia
Phase 1CompletedLB Pharmaceuticals Inc.642020-01-222020-12-10
Efficacy and Safety of Angong Niuhuang Wan for Stroke
Angong Niuhuang Wan, Angong Niuhuang Wan Placebo - Stroke (CVA) or TIA
Phase 2 / Phase 3UnknownChinese University of Hong Kong1002019-10-152021-01-29
Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis
X0002 Spray, Ibuprofen Tablet, Ibuprofen Placebo Tab - KNEE OSTEOARTHRITIS
Phase 2CompletedTianjin XinChen-Techfields Pharma Co., LTD.3532018-07-162020-01-13
Vitamin D Deficiency Treatment Outcomes After Non-ST-Segment Elevation Myocardial Infarction
Vitamin D3 50000 UNT Oral Capsule, Placebo oral capsule - Vitamin D Deficiency, Non-ST Elevation Myocardial Infarction (nSTEMI)
Phase 2UnknownIsfahan University of Medical Sciences702018-05-012018-08-20
Effects of Hormone Replacement Therapy on Arthralgia in Postmenopausal Women
Conjugated Equine Estrogen, Placebo - Arthralgia
Phase 2UnknownHospital de Clinicas de Porto Alegre722017-03-012019-10-14
A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes
TF0023 - Ischemic Stroke
Phase 2SuspendedTechfields Inc2252017-03-012024-01-05
Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Macitentan 10mg, Placebo sugar pill - Pulmonary Hypertension
Phase 2CompletedActelion572016-03-282025-03-30
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease
Deferiprone, Placebo - Parkinson Disease
Phase 2CompletedUniversity Hospital, Lille3722016-02-092026-02-05

Showing 20 of 29. Sign in to see all of them.

Conditions studied

Osteoarthritis, Knee (2)  ·  Pain, Postoperative (2)  ·  Parkinson Disease (2)  ·  Abdominal Pain (1)  ·  Agnosia (1)  ·  Arthralgia (1)  ·  Blood Coagulation Disorders (1)  ·  Breast Neoplasms (1)  ·  CDKL5 deficiency disorder (1)  ·  Colonic Neoplasms (1)  ·  Coronary Artery Disease, Autosomal Dominant, 1 (1)  ·  Cytomegalovirus Infections (1)  ·  Dyskinesias (1)  ·  Emergencies (1)  ·  Hyperkalemia (1)

Sponsors

EyePoint Pharmaceuticals, Inc. (2)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2)  ·  Ache Laboratorios Farmaceuticos S.A. (1)  ·  Actelion (1)  ·  Antlia Bioscience, Inc (1)  ·  Chinese University of Hong Kong (1)  ·  Christian Fenger-Eriksen (1)  ·  Claus Anders Bertelsen, PhD, MD (1)  ·  Comprehensive Research Associates (1)  ·  Guangzhou JOYO Pharma Co., Ltd (1)  ·  HB BioTech, LLC (1)  ·  Hospital de Clinicas de Porto Alegre (1)  ·  Immedica Pharma AB (1)  ·  Isfahan University of Medical Sciences (1)  ·  KAI Pharmaceuticals (1)

Countries

United States (12)  ·  Brazil (3)  ·  China (3)  ·  Denmark (2)  ·  France (2)  ·  Germany (2)  ·  New Zealand (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Czechia (1)  ·  Hong Kong (1)  ·  Hungary (1)  ·  India (1)

Top investigators

Chongxi Yu, Ph.D (1)  ·  Chongxi Yu, Ph.D. (1)  ·  Claus A Bertelsen, PhD (1)  ·  David Devos, MD, PhD (1)  ·  David Walling (1)  ·  Glenn Jaffe, MD (1)  ·  Gregory Bell, MD (1)  ·  Hermano Tavares (1)  ·  Jennifer K Chow, MD, MS (1)  ·  Jian Zhang, MD (1)  ·  Lukasz Biernat, MD (1)

Results publications

PMID 29380903, PMID 32624244, PMID 32726602, PMID 34851250, PMID 36449420, PMID 36517284, PMID 37308268, PMID 39542642, PMID 39635465, PMID 39952690, PMID 39994048, PMID 40629250, PMID 41316871, PMID 41730555

NIH funding

2015 (2), KL2TR003016 (1)